Get started
Author

Steve Horrigan

Observed names: S.K. Horrigan, Steven Horrigan
OpenAlex ID: A5061728022
Targeting nuclear β-catenin as therapy for post-myeloproliferative neoplasm secondary AML
2018 · Dyana T. Saenz, Warren Fiskus, et al. · Leukemia · 40
Abstract 6253: SP-3164, a novel molecular glue degrader with activity in preclinical models of multiple myeloma
2023 · Aundrietta D. Duncan, Daniela Y. Santiesteban, et al. · Cancer Research · 1
432 POSTER A small molecule allosteric inhibitor of Polo-like kinase 3 induces apoptosis and disrupts the integrity of the mitotic spindle apparatus in cancer cells
2008 · S.K. Horrigan, I. Lonskaya, et al. · European Journal of Cancer Supplements · 1
PT2.12.01 Osimertinib Combined With Tegavivint Is Safe and Tolerable as First-Line Therapy in Patients With Metastatic EGFR-Mutated NSCLC
2025 · R. Memmott, J. Gheeya, et al. · Journal of Thoracic Oncology
Pre-Clinical Efficacy of Targeting TBL1/R-β-Catenin-TCF7L2 Axis Against AML with 3q26 Lesions and EVI1 Overexpression
2021 · Christine Birdwell, Warren C. Fiskus, et al. · Blood
919 Tegavivint reduces the immunosuppressive macrophage phenotype in a preclinical co-culture model of the non-small cell lung cancer tumor microenvironment
2021 · Raghav Chandra, Josiah Flaming, et al. · Regular and Young Investigator Award Abstracts
PDF
Abstract 3036: BRD4 degrader and inhibitor of beta catenin-TCF7L2 are synergistically active against human AML cells resistant to BET inhibitor
2019 · Dyana T. Saenz, Warren C. Fiskus, et al. · Cancer Research
Abstract 3036: BRD4 degrader and inhibitor of beta catenin-TCF7L2 are synergistically active against human AML cells resistant to BET inhibitor
2019 · Dyana T. Saenz, Warren C. Fiskus, et al. · Experimental and Molecular Therapeutics
Novel BET Protein Degrader-Based Combinations Exert Lethality Against Human AML Resistant to BET Inhibitors Due to Increased Activity of β-Catenin-TCF7L2- MYC Axis
2018 · Dyana T. Saenz, Warren Fiskus, et al. · Blood
Genomic-based high throughput screening and identification of small molecule inhibitors targeting IFN α signaling pathways (131.17)
2007 · Bo Chen, Ricardo Cibotti, et al. · The Journal of Immunology
Biomarker-driven drug discovery: Identification and characterization of small molecule inhibitors against beta-catenin and Aurora kinase
2006 · Paul E. Young, Steve Horrigan, et al. · Cancer Research
103 High-throughput screening against intractable targets: the use of target disruption gene signatures for rapid cancer drug discovery
2004 · P.E. Young, J. Castaneda, et al. · European Journal of Cancer Supplements
Works count: 12
Citation count: 42
H-index: 1
I10-index: 1
Year
Topic
Type